BioNTech SE (BNTX) Goodwill & Intangibles (2018 - 2025)
BioNTech SE (BNTX) posted Goodwill & Intangibles of $2.3 billion for Q4 2025, up 12.47% sequentially from $2.0 billion in Q3 2025, and up 83.62% YoY from $1.3 billion in Q4 2024.
BioNTech SE (BNTX) Goodwill & Intangibles (2018 - 2025) Analysis & Trends
BioNTech SE has reported Goodwill & Intangibles for 8 years, with the latest figure at $2.3 billion in Q4 2025.
- Quarterly Goodwill & Intangibles rose 83.62% year-over-year to $2.3 billion in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $2.3 billion (up 83.62% YoY) and the FY2025 annual result came in at $2.2 billion, up 78.22% from the prior year.
- Goodwill & Intangibles rose to $2.3 billion in Q4 2025 per BNTX's latest filing, from $2.0 billion in the prior quarter.
- Over five years, Goodwill & Intangibles peaked at $2.3 billion in Q4 2025 and troughed at $192.1 million in Q3 2021.
- A 5-year average of $950.7 million and a median of $834.2 million in 2023 frame the typical range for Goodwill & Intangibles.
- The sharpest annual moves came in 2023 and 2024: Goodwill & Intangibles jumped 392.15% in 2023, then slipped 9.39% in 2024.
- Over 5 years, Goodwill & Intangibles stood at $294.2 million in 2021, then climbed by 2.85% to $302.6 million in 2022, then jumped by 356.36% to $1.4 billion in 2023, then retreated by 9.39% to $1.3 billion in 2024, then jumped by 83.62% to $2.3 billion in 2025.
- According to Business Quant data, Goodwill & Intangibles over the past three periods registered $2.3 billion, $2.0 billion, and $2.1 billion for Q4 2025, Q3 2025, and Q2 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Roivant Sciences | 26.20 Bn | 26.20 Bn | 1.16 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 2.30 Bn |
| Sep 30, 2025 | 2.04 Bn |
| Jun 30, 2025 | 2.10 Bn |
| Mar 31, 2025 | 1.99 Bn |
| Dec 31, 2024 | 1.25 Bn |
| Sep 30, 2024 | 1.37 Bn |
| Jun 30, 2024 | 1.33 Bn |
| Mar 31, 2024 | 1.29 Bn |
| Dec 31, 2023 | 1.26 Bn |
| Sep 30, 2023 | 1.12 Bn |
| Jun 30, 2023 | 545.99 Mn |
| Mar 31, 2023 | 406.37 Mn |
| Dec 31, 2022 | 302.61 Mn |
| Sep 30, 2022 | 228.07 Mn |
| Jun 30, 2022 | 236.25 Mn |
| Mar 31, 2022 | 242.42 Mn |
| Dec 31, 2021 | 294.23 Mn |
| Sep 30, 2021 | 192.11 Mn |
| Jun 30, 2021 | 197.62 Mn |
| Mar 31, 2021 | 199.27 Mn |